MCID: MSC012
MIFTS: 25

Muscular Dystrophy, Duchenne and Becker Type

Categories: Muscle diseases

Aliases & Classifications for Muscular Dystrophy, Duchenne and Becker Type

MalaCards integrated aliases for Muscular Dystrophy, Duchenne and Becker Type:

Name: Muscular Dystrophy, Duchenne and Becker Type 72
Duchenne and Becker Muscular Dystrophy 25 69
Muscular Dystrophy, Duchenne and Becker Types 25
Muscular Dystrophy, Pseudohypertrophic 25
Duchenne/becker Muscular Dystrophy 25
Dbmd 25

Classifications:



Summaries for Muscular Dystrophy, Duchenne and Becker Type

Genetics Home Reference : 25 Muscular dystrophies are a group of genetic conditions characterized by progressive muscle weakness and wasting (atrophy). The Duchenne and Becker types of muscular dystrophy are two related conditions that primarily affect skeletal muscles, which are used for movement, and heart (cardiac) muscle. These forms of muscular dystrophy occur almost exclusively in males.

MalaCards based summary : Muscular Dystrophy, Duchenne and Becker Type, also known as duchenne and becker muscular dystrophy, is related to muscular dystrophy and becker muscular dystrophy, and has symptoms including intellectual disability, mild, gait disturbance and joint stiffness. The drugs Carvedilol and Ramipril have been mentioned in the context of this disorder. Affiliated tissues include heart, skeletal muscle and bone.

Related Diseases for Muscular Dystrophy, Duchenne and Becker Type

Diseases related to Muscular Dystrophy, Duchenne and Becker Type via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 13)
id Related Disease Score Top Affiliating Genes
1 muscular dystrophy 11.1
2 becker muscular dystrophy 11.1
3 cardiomyopathy 10.2
4 duchenne muscular dystrophy 10.2
5 epilepsy 10.0
6 ischemia 10.0
7 muscular atrophy 10.0
8 fatty liver disease 10.0
9 myotonic dystrophy 10.0
10 glycerol kinase deficiency 10.0
11 dilated cardiomyopathy 10.0
12 liver disease 10.0
13 spinal muscular atrophy 10.0

Graphical network of the top 20 diseases related to Muscular Dystrophy, Duchenne and Becker Type:



Diseases related to Muscular Dystrophy, Duchenne and Becker Type

Symptoms & Phenotypes for Muscular Dystrophy, Duchenne and Becker Type

Human phenotypes related to Muscular Dystrophy, Duchenne and Becker Type:

32 (show all 13)
id Description HPO Frequency HPO Source Accession
1 intellectual disability, mild 32 occasional (7.5%) HP:0001256
2 gait disturbance 32 hallmark (90%) HP:0001288
3 joint stiffness 32 frequent (33%) HP:0001387
4 hypertrophic cardiomyopathy 32 frequent (33%) HP:0001639
5 developmental regression 32 occasional (7.5%) HP:0002376
6 scoliosis 32 frequent (33%) HP:0002650
7 slender long bone 32 frequent (33%) HP:0003100
8 myopathy 32 hallmark (90%) HP:0003198
9 skeletal muscle atrophy 32 hallmark (90%) HP:0003202
10 elevated serum creatine phosphokinase 32 hallmark (90%) HP:0003236
11 hyperlordosis 32 frequent (33%) HP:0003307
12 emg abnormality 32 hallmark (90%) HP:0003457
13 reduced bone mineral density 32 frequent (33%) HP:0004349

Drugs & Therapeutics for Muscular Dystrophy, Duchenne and Becker Type

Drugs for Muscular Dystrophy, Duchenne and Becker Type (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 200)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
2
Ramipril Approved Phase 4 87333-19-5 5362129
3
Tadalafil Approved, Investigational Phase 4,Phase 3,Phase 1,Early Phase 1 171596-29-5 110635
4 Adrenergic Agents Phase 4,Phase 3
5 Adrenergic alpha-1 Receptor Antagonists Phase 4
6 Adrenergic alpha-Antagonists Phase 4
7 Adrenergic Antagonists Phase 4
8 Adrenergic beta-Antagonists Phase 4
9 Antihypertensive Agents Phase 4,Phase 3,Phase 2
10 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
11 Vasodilator Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
12 Angiotensin-Converting Enzyme Inhibitors Phase 4,Phase 3,Phase 2
13 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2
14
protease inhibitors Phase 4,Phase 3,Phase 2
15 Phosphodiesterase 5 Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
16 Phosphodiesterase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
17 Anti-Bacterial Agents Phase 4,Phase 1
18 Antibiotics, Antitubercular Phase 4
19
Benzocaine Approved Phase 3 1994-09-7, 94-09-7 2337
20
Prednisone Approved, Vet_approved Phase 3,Phase 2 53-03-2 5865
21
Metformin Approved Phase 3,Phase 2,Phase 1 657-24-9 14219 4091
22
Enalapril Approved, Vet_approved Phase 3 75847-73-3 5362032 40466924
23
Enalaprilat Approved Phase 3 76420-72-9 6917719
24
Idebenone Approved, Investigational Phase 3,Phase 2 58186-27-9
25 Deflazacort Approved Phase 3,Phase 1 14484-47-0
26
Eplerenone Approved Phase 3 107724-20-9 150310 443872
27
Spironolactone Approved Phase 3 1952-01-7, 52-01-7 5833
28
Lisinopril Approved, Investigational Phase 2, Phase 3 83915-83-7, 76547-98-3 5362119
29
Zoledronic acid Approved Phase 3 118072-93-8 68740
30
Nebivolol Approved, Investigational Phase 3 152520-56-4, 99200-09-6, 118457-14-0 71301
31 tannic acid Approved, Nutraceutical Phase 3
32
Epigallocatechin gallate Investigational Phase 2, Phase 3 989-51-5 65064
33 Anti-Inflammatory Agents Phase 3,Phase 2,Phase 1
34 Bone Density Conservation Agents Phase 3,Phase 1
35 diuretics Phase 3,Phase 1
36 Natriuretic Agents Phase 3,Phase 1
37 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1
38 glucocorticoids Phase 3,Phase 2,Phase 1
39 Hormone Antagonists Phase 3,Phase 2,Phase 1
40 Hormones Phase 3,Phase 2,Phase 1
41 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1
42 Hypoglycemic Agents Phase 3,Phase 2,Phase 1
43 Antioxidants Phase 3,Phase 2,Phase 1
44 Micronutrients Phase 3,Phase 2
45 Protective Agents Phase 3,Phase 2,Phase 1
46 Trace Elements Phase 3,Phase 2
47 Ubiquinone Phase 3,Phase 2
48 Pharmaceutical Solutions Phase 2, Phase 3, Phase 1
49 Immunosuppressive Agents Phase 3,Phase 1
50 Diuretics, Potassium Sparing Phase 3

Interventional clinical trials:

(show top 50) (show all 208)

id Name Status NCT ID Phase Drugs
1 The Preventive Efficacy of Carvedilol on Cardiac Dysfunction in Duchenne Muscular Dystrophy Unknown status NCT00606775 Phase 4 Carvedilol
2 Ramipril Versus Carvedilol in Duchenne and Becker Patients Unknown status NCT00819845 Phase 4 carvedilol;ramipril
3 Tadalafil in Becker Muscular Dystrophy Completed NCT01070511 Phase 4 Tadalafil;Placebo
4 PDE5 Inhibition to Alleviate Functional Muscle Ischemia in Becker Muscular Dystrophy Completed NCT02207283 Phase 4 Tadalafil;Placebo
5 Stacking Exercises Aid the Decline in FVC and Sick Time Active, not recruiting NCT01999075 Phase 4
6 Effects of Sodium Nitrate on Blood Flow in Becker Muscular Dystrophy Unknown status NCT02147639 Phase 2, Phase 3
7 High-dose Prednisone in Duchenne Muscular Dystrophy Completed NCT00110669 Phase 3 Prednisone
8 L-citrulline and Metformin in Duchenne's Muscular Dystrophy Completed NCT01995032 Phase 3 750 mg metformin and 7.5 g L-citrulline daily p.o.;Placebo
9 Phase 2b Study of PTC124 in Duchenne/Becker Muscular Dystrophy (DMD/BMD) Completed NCT00592553 Phase 2, Phase 3 PTC124 High Dose;PTC124 Low Dose;Placebo
10 Phase III Randomized, Double-Blind Study of Prednisone for Duchenne Muscular Dystrophy Completed NCT00004646 Phase 3 prednisone
11 A Clinical Study to Assess the Efficacy and Safety of GSK2402968 in Subjects With Duchenne Muscular Dystrophy Completed NCT01254019 Phase 3 GSK2402968 6mg/kg/week
12 Myocardial Fibrosis Progression in Duchenne and Becker Muscular Dystrophy - ACE Inhibitor Therapy Trial Completed NCT02432885 Phase 3 Enalapril
13 Phase III Study of Idebenone in Duchenne Muscular Dystrophy (DMD) Completed NCT01027884 Phase 3 Placebo;Idebenone
14 Creatine and Glutamine in Steroid-Naive Duchenne Muscular Dystrophy Completed NCT00016653 Phase 2, Phase 3 Creatine Monohydrate;Glutamine
15 A Multicenter Randomized Placebo-Controlled Double-Blind Study to Assess Efficacy and Safety of Glutamine and Creatine Monohydrate in Duchenne Muscular Dystrophy (DMD) Completed NCT00018109 Phase 3 glutamine;creatine monohydrate
16 Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy Completed NCT01826487 Phase 3 Ataluren;Placebo
17 Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of BMS-986089 in Ambulatory Boys With Duchenne Muscular Dystrophy Recruiting NCT03039686 Phase 2, Phase 3
18 Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy Recruiting NCT02851797 Phase 3 givinostat;placebo
19 A Phase III Double-blind Study With Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Taking Glucocorticoid Steroids Recruiting NCT02814019 Phase 3 Idebenone 150 mg film-coated tablets;placebo
20 Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy Recruiting NCT03179631 Phase 3 Ataluren;PLACEBO
21 Study of SRP-4045 and SRP-4053 in DMD Patients Recruiting NCT02500381 Phase 3 SRP-4045;SRP-4053;Placebo
22 1 Year Open-label Extension to CZOL446H2337 Safety and Efficacy Trial of Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids Recruiting NCT01197300 Phase 3 zoledronic acid
23 A Research Study of Zoledronic Acid in Children and Adolescents With Osteoporosis Recruiting NCT00799266 Phase 3 Zoledronic acid;Placebo
24 Confirmatory Study of Eteplirsen in DMD Patients Active, not recruiting NCT02255552 Phase 3 eteplirsen
25 Finding the Optimum Regimen for Duchenne Muscular Dystrophy Active, not recruiting NCT01603407 Phase 3 Prednisone;Prednisone;Deflazacort
26 Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy Active, not recruiting NCT02354352 Phase 3 Eplerenone;Spironolactone
27 Sunphenon Epigallocatechin-Gallate (EGCg) in Duchenne Muscular Dystrophy Active, not recruiting NCT01183767 Phase 2, Phase 3 Epigallocatechin-Gallate;Placebo
28 Nebivolol for the Prevention of Left Ventricular Systolic Dysfunction in Patients With Duchenne Muscular Dystrophy Active, not recruiting NCT01648634 Phase 3 Nebivolol;Placebo
29 Study of Ataluren for Previously Treated Patients With nmDBMD in Europe, Israel, Australia, and Canada Active, not recruiting NCT01557400 Phase 3 Ataluren
30 Phase 3 Extension Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy Active, not recruiting NCT02090959 Phase 3 Ataluren
31 Study of Ataluren for Previously Treated Patients With nmDBMD in the US Enrolling by invitation NCT01247207 Phase 3 Ataluren
32 Clinical Trial of Coenzyme Q10 and Lisinopril in Muscular Dystrophies Enrolling by invitation NCT01126697 Phase 2, Phase 3 Coenzyme Q10 and Lisinopril
33 Phase 2b Extension Study of Ataluren (PTC124) in Duchenne/Becker Muscular Dystrophy (DMD/BMD) Terminated NCT00847379 Phase 2, Phase 3 Ataluren (PTC124)
34 A Study of Tadalafil for Duchenne Muscular Dystrophy Terminated NCT01865084 Phase 3 Tadalafil;Placebo
35 Extension Study of Drisapersen in DMD Subjects Terminated NCT02636686 Phase 3 Drisapersen
36 CoQ10 and Prednisone in Non-Ambulatory DMD Terminated NCT00308113 Phase 3 Prednisone
37 Open Label Study of GSK2402968 in Subjects With Duchenne Muscular Dystrophy Terminated NCT01480245 Phase 3 GSK2402968
38 A Study of the Safety, Tolerability & Efficacy of Long-term Administration of Drisapersen in US & Canadian Subjects Terminated NCT01803412 Phase 3 Drisapersen;Drisapersen;Drisapersen
39 Evaluation of a Mechanical Device During Acute Respiratory Failure in Patients With Neuromuscular Disorders Terminated NCT00839033 Phase 3
40 Drisapersen Duchenne Muscular Dystrophy (DMD) Treatment Protocol Withdrawn NCT01890798 Phase 3 Drisapersen
41 Efficacy of Umbilical Cord Mesenchymal Stem Cells in Duchenne Muscular Dystrophy Unknown status NCT02285673 Phase 1, Phase 2
42 Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Duchenne Muscular Dystrophy Unknown status NCT01610440 Phase 1, Phase 2
43 Safety and Efficacy Study of IGF-1 in Duchenne Muscular Dystrophy Unknown status NCT01207908 Phase 1, Phase 2 IGF-1
44 Study Safety and Efficacy of BMMNC for the Patient With Duchenne Muscular Dystrophy Unknown status NCT01834040 Phase 1, Phase 2
45 Phase II Study of NPC-14 (Arbekacin Sulfate) to Explore Safety, Tolerability, and Efficacy in Duchenne Muscular Dystrophy Unknown status NCT01918384 Phase 2 NPC-14;Placebo
46 Study Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Muscular Dystrophy. Unknown status NCT01834066 Phase 1, Phase 2
47 Safety and Efficacy Study of PTC124 in Duchenne Muscular Dystrophy Completed NCT00264888 Phase 2 PTC124
48 Safety and Efficacy Study of Antisense Oligonucleotides in Duchenne Muscular Dystrophy Completed NCT00159250 Phase 1, Phase 2 AVI-4658 (PMO)
49 Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy Patients Completed NCT01396239 Phase 2 AVI-4658 (Eteplirsen)
50 Phase I/II Study of PRO044 in Duchenne Muscular Dystrophy (DMD) Completed NCT01037309 Phase 1, Phase 2 PRO044 SC;PRO044 IV

Search NIH Clinical Center for Muscular Dystrophy, Duchenne and Becker Type

Genetic Tests for Muscular Dystrophy, Duchenne and Becker Type

Anatomical Context for Muscular Dystrophy, Duchenne and Becker Type

MalaCards organs/tissues related to Muscular Dystrophy, Duchenne and Becker Type:

39
Heart, Skeletal Muscle, Bone, Testes

Publications for Muscular Dystrophy, Duchenne and Becker Type

Variations for Muscular Dystrophy, Duchenne and Becker Type

Copy number variations for Muscular Dystrophy, Duchenne and Becker Type from CNVD:

7 (show all 41)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 262120 X 31046000 31495434 Deletion Duchenne and Becker muscular dystrophies
2 262121 X 31046000 31499751 Deletion Duchenne and Becker muscular dystrophies
3 262151 X 31503750 31715250 Duplication Duchenne and Becker muscular dystrophies
4 262152 X 31518523 31948537 Deletion Duchenne and Becker muscular dystrophies
5 262154 X 31533250 31645750 Deletion Duchenne and Becker muscular dystrophies
6 262156 X 31555638 31864405 Deletion Duchenne and Becker muscular dystrophies
7 262157 X 31563750 31981750 Deletion Duchenne and Becker muscular dystrophies
8 262158 X 31573250 31702250 Deletion Duchenne and Becker muscular dystrophies
9 262159 X 31578750 31989750 Deletion Duchenne and Becker muscular dystrophies
10 262160 X 31584297 31995179 Deletion Duchenne and Becker muscular dystrophies
11 262162 X 31607250 31615750 Deletion Duchenne and Becker muscular dystrophies
12 262163 X 31608059 31811249 Deletion Duchenne and Becker muscular dystrophies
13 262164 X 31620852 31877576 Deletion Duchenne and Becker muscular dystrophies
14 262165 X 31637403 31824256 Deletion Duchenne and Becker muscular dystrophies
15 262166 X 31641000 31661000 Deletion Duchenne and Becker muscular dystrophies
16 262168 X 31703750 31969750 Deletion Duchenne and Becker muscular dystrophies
17 262169 X 31720250 32212750 Duplication Duchenne and Becker muscular dystrophies
18 262170 X 31723560 31799723 Deletion Duchenne and Becker muscular dystrophies
19 262171 X 31736096 31781840 Deletion Duchenne and Becker muscular dystrophies
20 262172 X 31736250 31784750 Deletion Duchenne and Becker muscular dystrophies
21 262192 X 31797750 31939750 Deletion Duchenne and Becker muscular dystrophies
22 262193 X 31838750 32014750 Deletion Duchenne and Becker muscular dystrophies
23 262194 X 31855778 32003438 Deletion Duchenne and Becker muscular dystrophies
24 262195 X 31867000 32037000 Deletion Duchenne and Becker muscular dystrophies
25 262216 X 32030750 32191750 Duplication Duchenne and Becker muscular dystrophies
26 262218 X 32073457 32469353 Deletion Duchenne and Becker muscular dystrophies
27 262219 X 32094750 32474250 Deletion Duchenne and Becker muscular dystrophies
28 262221 X 32098595 32181888 Deletion Duchenne and Becker muscular dystrophies
29 262252 X 32275827 32453261 Duplication Duchenne and Becker muscular dystrophies
30 262255 X 32313750 32622750 Deletion Duchenne and Becker muscular dystrophies
31 262265 X 32425250 32488250 Deletion Duchenne and Becker muscular dystrophies
32 262267 X 32444250 32455250 Deletion Duchenne and Becker muscular dystrophies
33 262279 X 32521250 32633250 Deletion Duchenne and Becker muscular dystrophies
34 262281 X 32561500 32628500 Duplication Duchenne and Becker muscular dystrophies
35 262282 X 32572850 32629450 Duplication Duchenne and Becker muscular dystrophies
36 262283 X 32575950 32719450 Deletion Duchenne and Becker muscular dystrophies
37 262284 X 32662600 32842800 Deletion Duchenne and Becker muscular dystrophies
38 262285 X 32676750 32794750 Duplication Duchenne and Becker muscular dystrophies
39 262288 X 32706289 32779413 Deletion Duchenne and Becker muscular dystrophies
40 262291 X 32761242 33013846 Duplication Duchenne and Becker muscular dystrophies
41 262292 X 32761250 33026750 Duplication Duchenne and Becker muscular dystrophies

Expression for Muscular Dystrophy, Duchenne and Becker Type

Search GEO for disease gene expression data for Muscular Dystrophy, Duchenne and Becker Type.

Pathways for Muscular Dystrophy, Duchenne and Becker Type

GO Terms for Muscular Dystrophy, Duchenne and Becker Type

Sources for Muscular Dystrophy, Duchenne and Becker Type

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....